AptarGroup crossed a meaningful threshold in the second quarter - net sales of $1.03 billion against $966 million a year earlier, the first time the drug-delivery and dispensing specialist has printed a single quarter above the $1 billion mark. The first billion is the headline. It is also almost the entire story the market should not be reading. Reported sales rose 6%, but roughly two points of that was a weaker U.S. dollar, another three was a recent acquisition in Beauty, and underlying core sales - the metric management uses and adjusts for both - grew just 1%. Every one of the three reporting segments expanded the top line and every one of them lost adjusted EBITDA margin to get there: Pharma's adjusted EBITDA margin fell 180 basis points to 33.6%, Beauty's fell 190 to 12.2%, and Closures' fell 200 to 14.9%. The consolidated adjusted EBITDA margin compressed 190 basis points to 20.7%, and adjusted earnings per share fell 15% to $1.42. Reported diluted EPS of $1.36 fell 19% from $1.67. Reported growth was real. Core growth was almost nothing. Margins were the cost of getting either.
Two structural events sit on top of the quarter. Stephan Tanda, Aptar's CEO since 2017, is handing the company to Gael Touya on September 1; this was Tanda's last quarterly print, and his remarks carried the slightly ceremonial tone of a handoff. Separately, the emergency-medicine destocking that has been depressing the Pharma segment's prescription drug sales for several quarters is, management said, on track to "abate by the fourth quarter" - a load-bearing claim, because emergency-medicine is one of Pharma's higher-margin product lines and its drag is the single largest explanation for the consolidated margin compression. The two events point in the same direction: a CEO transition that begins right when the company needs its margin recovery thesis to start proving itself.
The capital-return story did its job. Aptar returned $81 million to shareholders in the quarter ($50 million of buybacks plus the dividend) and $212 million in the half ($150 million of buybacks plus $61.5 million of dividends). The board refreshed the buyback authorization to $600 million in February and $450 million remains. The dividend runs at $0.48 a quarter. At a reference price of $131.82, the implied dividend yield is roughly 1.5%, and the annualized buyback pace is around 2% of the equity - not aggressive, but a steady reminder that the cash is going back to shareholders rather than into emergency-medicene inventory. The first billion is a milestone worth noting. The next two quarters, when the new CEO owns the print and the emergency-medicine overhang either lifts or doesn't, are the ones that tell the story.